Navegando por Palavras-chave "valproic acid"

Agora exibindo 1 - 2 de 2
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Effects of valproic acid on an animal model of tardive dyskinesia
    (Elsevier B.V., 2003-06-16) Peixoto, M. F.; Abilio, V. C.; Silva, R. H.; Frussa, R.; Universidade Federal de São Paulo (UNIFESP)
    GABAergic hypofunction in the basal ganglia is stated as an important mechanism underlying the pathophysiology of tardive dyskinesia. the present study investigates the effects of the GABA-mimetic drug valproic acid (VA) on the manifestation of reserpine-induced orofacial movements, an animal model of tardive dyskinesia. Male Wistar rats received two injections of control solution or of 1 mg/kg reserpine separated by 48 h. Twenty-four hours later, animals were acutely treated with 50, 100, or 200 mg/kg VA or control solution and were observed for quantification of orofacial movements and of open-field general activity. the highest dose of VA inhibited the manifestation of reserpine-induced orofacial movements but none of the VA doses modified reserpine-induced decrease in open-field general activity. These results support the potential of VA as an effective pharmacological tool in the treatment of tardive dyskinesia. (C) 2003 Elsevier Science B.V. All rights reserved.
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Uso potencial dos anticonvulsivantes no tratamento ambulatorial da dependência de álcool
    (Instituto de Psiquiatria da Universidade Federal do Rio de Janeiro, 2006-01-01) Castro, Luís André [UNIFESP]; Couzi, Carla [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    Currently three medications (disulfiram, naltrexone and acamprosate) are approved by the FDA to treat alcohol dependence by the FDA. The classical anticonvulsive drugs are rarely employed as an alternative because of their side effects, but the latest generation of anticonvulsants could be useful. The anticonvulsants can be a alternative to BZD and other pharmacological treatments in the prevention of complications during the detoxification therapy, because of the absence of addictive properties and a better adverse effects profile than classical anticonvulsant drugs. Anticonvulsants such as carbamazepine, valproic acid, gabapentin and topiramate have shown to be excellent treatment for alcohol withdrawal and for the prevention of alcohol relapse. Although none of these agents have been approved by the FDA yet, there is growing evidence in the literature to support their use.